Gonwa T A, Klintmalm G B, Levy M, Jennings L S, Goldstein R M, Husberg B S
Transplantation Services, Baylor University Medical Center, Dallas, Texas 75246.
Transplantation. 1995 Feb 15;59(3):361-5.
To determine the effect of pretransplant liver function on survival following orthotopic liver transplantation and to quantify the effects of cyclosporine administration on long-term renal function in patients undergoing liver transplant, we performed an analysis of a prospectively maintained database. Data from 569 consecutive patients undergoing liver transplantation alone who were treated with CsA for immunosuppression were used for this study. Actuarial graft and patient survival rates were calculated using Kaplan-Meier statistics. Glomerular filtration rates, serum creatinine, and the use of various immunosuppressives were analyzed for this study. The initial analysis demonstrated that patients presenting for liver transplant with hepatorenal syndrome have a significantly decreased acturial patient survival after liver transplant at 5 years compared with patients without hepatorenal syndrome (60% vs. 68%, P < 0.03). Patients with hepatorenal syndrome recovered their renal function after liver transplant. Patients who had hepatorenal syndrome were sicker and required longer stays in the intensive care unit, longer hospitalizations, and more dialysis treatments after transplantation compared with patients who did not have hepatorenal syndrome. The incidence of end-stage renal disease after liver transplantation in patients who had hepatorenal syndrome was 7%, compared with 2% in patients who did not have hepatorenal syndrome. To more fully examine the effect of pretransplant renal function on posttransplant survival, the non-hepatorenal syndrome patients were divided into quartiles depending upon their pretransplant renal function. The patients with the lowest pretransplant renal function had the same survival as the patients with the highest pretransplant renal function. In addition, there was no increased incidence of acute or chronic rejection in any of the groups. The patients with the lower pretransplant renal function were treated with more azathioprine to maintain renal function and had a negligible decrease in glomerular filtration rate following transplant. Conversely, patients with the highest level of renal function pretransplant had a 40% decline in renal function in the first year, but maintained stable renal function up to 4 years after transplant. We conclude that pretransplant renal function other than hepato-renal syndrome has no effect on patient survival after orthotopic liver transplant. Renal function after liver transplant is stable after an initial decline, despite continued administration of CsA.(ABSTRACT TRUNCATED AT 400 WORDS)
为了确定肝移植前肝功能对原位肝移植术后生存率的影响,并量化环孢素给药对肝移植患者长期肾功能的影响,我们对一个前瞻性维护的数据库进行了分析。本研究使用了569例连续接受单纯肝移植且接受环孢素免疫抑制治疗患者的数据。采用Kaplan-Meier统计方法计算精算移植和患者生存率。本研究分析了肾小球滤过率、血清肌酐以及各种免疫抑制剂的使用情况。初步分析表明,与无肝肾综合征的患者相比,因肝肾综合征行肝移植的患者肝移植术后5年的精算患者生存率显著降低(60%对68%,P<0.03)。肝肾综合征患者肝移植后肾功能恢复。与无肝肾综合征的患者相比,有肝肾综合征的患者病情更重,在重症监护病房停留时间更长、住院时间更长,移植后需要更多的透析治疗。有肝肾综合征的患者肝移植后终末期肾病的发生率为7%,而无肝肾综合征的患者为2%。为了更全面地研究肝移植前肾功能对移植后生存的影响,将非肝肾综合征患者根据其肝移植前肾功能分为四分位数。肝移植前肾功能最差的患者与肝移植前肾功能最好的患者生存率相同。此外,任何一组中急性或慢性排斥反应的发生率均未增加。肝移植前肾功能较低的患者使用更多的硫唑嘌呤来维持肾功能,移植后肾小球滤过率下降可忽略不计。相反,肝移植前肾功能水平最高的患者在第一年肾功能下降40%,但移植后4年内肾功能保持稳定。我们得出结论,肝肾综合征以外的肝移植前肾功能对原位肝移植术后患者生存率无影响。尽管持续给予环孢素,但肝移植后肾功能在最初下降后保持稳定。(摘要截短至400字)